Zhou indicated that activation of ActRIIB (receptor for activin and myostatin) contributes to the loss of mass in cancer cachexia model mice and that an ActRIIB antagonist may be a therapeutic approach to the treatment of cancer cachexia (Zhou et al., 2010). Here, ACVR2B is linked to cancer.